



Harpreet Bajaj MBBS, MPH, ECNU, FACE

* Harpreet Bajaj provides medical services through Dr. Harpreet Bajaj Medicine Professional Corporation

Brampton 2979 Bovaird Drive East, Brampton, Ontario, L6S 0C6, Canada

Tel (905) 595-0560

CURRICULUM VITAE

Education, Certification & Licenses

2019-2021	ICH-GCP Training	Syneos
2019	Re-certification in Endocrinology, Diabetes and Metabolism	American Board of Internal Medicine
2013	Fellow (FACE)	American College of Endocrinology
2011	Endocrine Certification in Neck Ultrasound (ECNU)	American College of Endocrinology
2009	Certification in Endocrinology, Diabetes and Metabolism	American Board of Internal Medicine
2009	Certification	College of Physicians and Surgeons of Ontario
2009	Certification in Clinical Densitometry	International Society for Clinical Densitometry
Jun 2007-Jun 2009	Clinical Fellowship in endocrinology, Diabetes and Metabolism	Cleveland Clinic, USA
2007	Certification in Protection of Human Research Subjects	CITI
2007	Certification in Internal Medicine	American Board of Internal Medicine
Jun 2004- Jun 2007	Clinical Internship and Residency in Internal medicine	Hennepin County Medical Center, USA
Sep 2002-May 2004	Master of Public Health (MPH), Epidemiology	University of Albany SUNY, USA
2003	Certification	Education Commission for Foreign Medical Graduates
Aug 1995-Dec 1999	Bachelor of Medicine and Bachelor of Surgery	Maulana Azad Medical College, University of Delhi, India

Professional Activities*

Jan 2019-Present	Vice-Chair, Clinical Practice Guidelines	Diabetes Canada, Toronto ON
2019-Present	National Leader	Eli Lilly – GPGN trial
2019-Present	National Leader	Novo Nordisk – SOUL trial
2018-Present	National Coordinator	Sanofi-Amplitude-O Trial
Dec 2018-Present	Director-Late Phase Research	LMC Clinical Research Inc.
Jul 2009-Present	Principal Investigator	LMC Clinical Research Inc.
Jul 2009-Present	Associate Endocrinologist	LMC Diabetes & Endocrinology
Sep 2017-Present	Columnist and Endocrinology Ad-Board Member	Medscape & WedMD
Mar 2016-Present	Research Associate	Mount Sinai Hospital, Toronto ON
Oct 2015-Present	National Consultant Editor	Canadian Journal of Diabetes
2014-Present	Founding Chairman	“STOP Diabetes” Foundation Inc.

Publications**

Bajaj HS, Wiviott SD, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Nilsson IG, Sabatine MS, Raz I, Cahn A. Cardiovascular and renal benefits of dapagliflozin in patients with short and long standing diabetes: analyses from the DECLARE TIMI 58 trial. *Diabetes Obes Metab* 2020

Jardine MJ, Zhou Z, Mahaffey KW, Agarwal R, Bakris, G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler TC, Zhang H, Zinman B, Rosenthal N, Perkovic V. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin By Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. *Journal of the American Society of Nephrology*. 2020

Phillis-Tsimikas, A., Klonoff, DC., Khunti, K., Bajaj HS, Leiter L, Hansen M, Troelsen LN, Ladellund S, Heller S, Pieber TR. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. *Diabetologia*. 2020 Jan 27

Brown RE, Abitbol A, Bajaj HS, Goldenberg R, Khandwala H, Abdel-Salam S, Aronson R; Patient Reported Outcomes Following Initiation of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes in a Specialist Endocrinology Practice of the LMC Diabetes Registry: The PROGRESS-Diabetes Study. *Diabetes Res Clin Pract*. 2019 Oct;156:10782

Bajaj HS, Barnes T, Nagpal S, Tricco AC, Rios P, Porr C, Senior P, Huot C; Diabetes Canada Position Statement on Recreational Cannabis Use in Adults and Adolescents with Type 1 and Type 2 Diabetes. *Can J Diabetes*. 2019 Aug;43(6):372-376

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD; Rose JB, Sorabji D, Bajaj HS; CANadian CANagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice. *Can J Diabetes*. *Can J Diabetes*. 2019 Apr 16

Dailey G, Bajaj HS, Dex T, Groleau M, Stager W, Vinik A; Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed-ratio combination in North American patients compared with the rest of world. *BMJ Open Diabetes Research and Care* 2019;7:e000581. doi: 10.1136/bmjdr-2018-000581

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD; Rose JB, Rapattoni W, Bajaj HS; *CANadian CANagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice*. *Diabetes Obes Metab*. 2019 Mar;21(3):691-699

Bajaj HS, Abouhassan T, Ahsan MR, Arnaut A, Hassanein M, Houlden RL, Khan T, Khandwala H, Verma S; *Diabetes Canada Position Statement for People with Types 1 and 2 Diabetes Who Fast During Ramadan*. *Can J Diabetes*. 2019 Feb;43(1):3-12

Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R; *SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes*. *Diabetes and Metabolism*. 2018 Dec;44(6):493-499

Bajaj HS, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R; *Biomarkers of Vascular Injury after Recent Glucose Intolerance in Pregnancy*; *Diabetes and Vascular Disease Research* 2018 Sep;15(5):449-457

Clinical Trials & Research Activities

2009-2020 R331333-PAI-3027 (J&J), H80-CA-GWCE (Lilly), TRX4-DM-006-NA-08 (GSK), EMERGE 8 (Roche), 28431754-DIA-3012 (J&J), 1245.23 (BI), 28431754-DIA-3015 (J&J), 1245.31 (BI), H9X-MC-GBDJ (Eli Lilly), EFC 1162 (Sanofi-aventis), D1693C00005 (AstraZeneca), 1245.48 (BI), EFC 12261 (Sanofi-Aventis), TAK-875_306 (Takeda), RGN1110 (Regeneron), RGN1118 (Regeneron), D1693C00001 (AstraZeneca), EFC 12626 (Sanofi-Aventis), M11-352 (Abbvie), B1481022 (Pfizer), B1481038 (Pfizer), INNOVATE (LMC Diabetes&Endocrinology), APD356-G000-401(Eisai), GSN000200 (Genkyotex), MK-8835-002 (Merck), 28431754DNE3001 (Janssen), EFC12405 (Sanofi-Aventis), EFC13799 (Sanofi-Aventis), B1481038 (Pfizer), B1481022 (Pfizer), 200977 (GSK), B1481045 (Pfizer), D1690C00024 (AstraZeneca), Merck 139 (Merck Frosst), MB102-029 (BMS), AVD111960 (GSK), 1218.62 (BI), EFC10781 (Sanofi-aventis), GOAL_RCT (LMC Diabetes & Endocrinology), MK-0431-845 (Merck), LPS14347 (Sanofi), D169AC00001 (AstraZeneca), EFC14837 (Sanofi), NN1250-4252 (Novo Nordisk), NN9924-4280 (Novo Nordisk), K-877-302 (KOWA), EFC14875 (Sanofi), NN9535-4269 (Novo Nordisk), EFC14868 (Sanofi), TRCA-303 (Tricidia), NN1436-4386 (Novo Nordisk), CAN-TREAT (Novo Nordisk), Variation 2 (LMC), EFC14828 (Sanofi), OBS16040 (Sanofi), LPS15544 (Sanofi), I8F-MC-GPGM (Eli Lilly), 1245-0137 (BI), 1404-002 (BI), GS-US-223-1017 (Gilead), MGL-3196-11 (Madrigal), PROJ1601 (BetAvena), EX9924-4473 (Novo Nordisk), NN9535-4321 (Novo Nordisk), NN9535-4506 (Novo Nordisk), 20170625 (Amgen), NN1436-4466 (Novo Nordisk), etc.

Cleveland Clinic, Cleveland, OH(Diabetes, Multiple Sclerosis, Metabolism, Endocrinology), Hennepin County Medical Center, Minneapolis, MN(Diabetes), University of Minnesota, Minneapolis, MN(Endocrinology), New York State Department of Health, NY(Lyme Disease), Lok Nayak Hospital, New Delhi, India(Asthma), Indian Council of Medical Research (ICMR), Dept. of Regenerative Surgery, India(Neo-organogenesis using stem cells from developed tissue)

*>20 Appointments & Teaching Positions & >15 Volunteer Positions in Public Health education and Advocacy

**>23 Peer-reviewed Publications & >86 Extramural Invited Abstracts & Presentations